DNA methylation processes

DNA methylation is a fundamental epigenetic modification involving the addition of a methyl group to the 5-carbon position of cytosine residues in DNA, catalyzed by DNA methyltransferase enzymes such as DNMT1, DNMT3A, and DNMT3B[1][3][5][6][8]. Methylation predominantly occurs at CpG dinucleotides and can stably repress gene transcription, influence chromatin structure, and direct cell differentiation and tissue-specific gene expression[1][3][6]. These processes are reversible by enzymes in the TET family that oxidize methylcytosine, and are crucial for biological functions such as imprinting, embryonic development, and maintenance of genome stability[1][4][8]. Aberrant DNA methylation is implicated in a wide range of diseases, including cancers, by silencing tumor suppressor genes, as well as neurodegenerative and developmental disorders[1][7]. Although drugs target the enzymes mediating methylation, "DNA methylation processes" themselves are not considered a single canonical therapeutic target, but rather a critical pathway and analytical biomarker in translational medicine[7][10]. This entry is not a specific molecule, receptor, or therapeutic target but refers to a set of dynamic enzymatic processes essential for epigenetic regulation. For structured data, individual components such as "DNA methyltransferase 1 (DNMT1)," "DNA methyltransferase 3A (DNMT3A)," or "Ten-eleven translocation methylcytosine dioxygenase (TET)" should be considered as specific molecular targets.

Other names

DNA methylationDNA methylation mechanismDNA methylation pathwayepigenetic methylationCpG methylation

Inhibition of DNA methyltransferase enzymes (DNMT inhibitors block methyl group transfer to DNA)[7][5]